Remote Patient Monitoring Is Going Consumer: How Wearables Are Crossing the Clinical Divide

In September 2025, the FDA cleared Apple Watch to detect hypertension — the condition affecting nearly half of American adults and contributing to more deaths than any other modifiable risk factor [1]. The algorithm was trained on data from over 100,000 people, validated in a 2,000-participant study, and will be available across 150+ countries on devices that hundreds of millions of people already own [1].

A month earlier, Aktiia received FDA clearance for the first cuffless blood pressure monitor sold over the counter — no prescription, no doctor’s office, no arm cuff [2].

These aren’t incremental product updates. They represent a structural shift: consumer wearable devices are becoming clinical monitoring tools. The device on your wrist that tracks steps and sleep is increasingly the same device that screens for cardiovascular disease, detects atrial fibrillation, and monitors blood oxygen levels.

The remote patient monitoring market — which saw Medicare claims grow 555% between 2019 and 2022 [3] — is converging with the consumer wearable market. The implications for health data infrastructure, product design, and the business models built around health data are significant.

The RPM market today

Remote patient monitoring has been one of the fastest-growing segments in healthcare technology, driven by reimbursement policy, chronic disease prevalence, and patient preference.

Reimbursement as the engine

CMS expanded RPM reimbursement codes in 2019, creating a financial framework for healthcare providers to bill for remote monitoring services. Reimbursement rates were increased by 10% in 2021. The result: Medicare RPM claims grew from a niche category to one of the fastest-expanding billing codes in the system [3].

The reimbursement model covers device setup, monthly data transmission (minimum 16 days of data per month), and clinical staff time reviewing and acting on the data. For healthcare organizations, RPM represents both a clinical improvement tool and a revenue opportunity.

Clinical need

Approximately 60% of U.S. adults have at least one chronic condition. Cardiovascular disease alone accounts for over 919,000 deaths annually [4]. The traditional model — periodic office visits where a blood pressure reading or glucose level is captured once every few months — misses the daily variability that drives acute events and disease progression.

Continuous monitoring catches what periodic measurement misses: the blood pressure spike that happens at 3am, the glucose variability between meals, the HRV depression that precedes a cardiac event. The clinical case for continuous data is well-established; the constraint has been getting monitoring devices into patients’ daily lives.

Patient preference

The data on patient acceptance is clear: 53% of patients prefer RPM over traditional office visits, and 70% are willing to share health data for personalized remote monitoring [3]. The preference isn’t surprising — RPM means fewer trips to the doctor, less disruption to daily life, and more timely clinical attention when data shows something concerning.

The consumer-clinical convergence

The RPM market historically relied on dedicated medical devices: FDA-cleared blood pressure cuffs, pulse oximeters, glucose meters, and weight scales that transmit data to a clinical platform. These devices work, but they’re single-purpose, clinical in appearance, and carry the stigma of being “medical equipment.”

Consumer wearables are erasing this boundary.

Apple Watch as a clinical device

The Apple Watch now carries three FDA clearances relevant to clinical monitoring:

• ECG (cleared 2018) — detects atrial fibrillation, a leading cause of stroke
• Blood oxygen (cleared 2020) — monitors SpO2, relevant to respiratory conditions and sleep apnea
• Hypertension notification (cleared 2025) — analyzes blood vessel response patterns over 30 days to alert users to potential high blood pressure [1]

The hypertension feature is particularly significant because of its reach. High blood pressure affects nearly half of American adults, and approximately half of those don’t know they have it. A screening tool that runs passively on a device worn by hundreds of millions of people has population-health implications that dedicated medical devices can’t match.

Cuffless blood pressure monitoring

Aktiia’s Hilo Band — the first FDA-cleared cuffless blood pressure monitor for over-the-counter sale — represents a category creation moment [2]. Blood pressure has been measured the same way for over a century: inflate a cuff around the arm, listen for pulse sounds, record the numbers. Cuffless monitoring using optical sensors on the wrist makes continuous blood pressure tracking feasible for the first time outside a clinical setting.

The implications extend beyond convenience. Continuous blood pressure data reveals patterns that spot measurements miss: nocturnal dipping (or non-dipping, a cardiovascular risk marker), morning surges, white coat effects, and the impact of stress, exercise, and meals on blood pressure throughout the day. This data resolution transforms blood pressure from a periodic check into a continuous health signal.

The blurring boundary

The trend is accelerating. Samsung is pursuing FDA clearance for blood pressure monitoring on the Galaxy Watch. Google’s Fitbit platform has clinical research capabilities built in. Oura is partnering with clinical research institutions. Garmin devices are being used in clinical trials.

The direction is unmistakable: the consumer wearable is becoming the primary clinical monitoring device for outpatient care. Not replacing hospital-grade equipment for acute care, but replacing the dedicated home medical devices that patients were supposed to use (and often didn’t) for chronic condition management.

What this means for health data

The consumer-clinical convergence creates new requirements for health data infrastructure that sits between the device and the clinical or product application.

Clinical-grade data pipelines

When wearable data feeds clinical decisions, the data pipeline must meet clinical standards: accuracy, completeness, timeliness, and audit trail. A missed data transmission that’s irrelevant for a fitness app becomes clinically significant for hypertension monitoring. The infrastructure that processes and delivers health data needs to handle both wellness and clinical use cases without separate pipelines.

Continuous vs. periodic processing

Traditional RPM platforms process data in batches — daily summaries, weekly reports. Consumer wearable data arrives continuously. The processing infrastructure needs to handle both: real-time alerting for acute signals (a dangerous heart rate, a blood oxygen drop) and longitudinal analysis for chronic management (blood pressure trends over months, HRV trajectory over weeks).

Multi-device, multi-source normalization

Patients don’t use one device consistently. They switch between Apple Watch and Oura Ring, add a CGM temporarily, use a blood pressure cuff at the doctor’s office and a cuffless monitor at home. Clinical-grade health data requires normalization across these sources — ensuring that trend data remains consistent and comparable regardless of which device generated it.

Privacy and consent at clinical scale

Consumer health data used for clinical purposes crosses into healthcare privacy regulation. Data that was collected under a wellness app’s terms of service may require different consent frameworks when it’s used for clinical monitoring. The data infrastructure needs to support granular consent management and comply with HIPAA when data enters the clinical pathway.

The product opportunity

For health app developers

Health apps that already collect wearable data are sitting on clinically relevant information. Sleep data, HRV trends, activity patterns, and resting heart rate all carry signals relevant to chronic disease management. Product teams don’t need to become medical device companies — but they can provide the health data layer that clinical RPM platforms consume.

For RPM platform providers

The shift from dedicated medical devices to consumer wearables fundamentally changes the RPM value proposition. Instead of shipping patients a box of medical devices and hoping they use them, RPM providers can leverage the devices patients already wear. The challenge shifts from device logistics to data integration — connecting consumer wearable data into clinical workflows.

For employers and insurers

RPM has traditionally been a post-diagnosis intervention. Consumer wearables enable pre-diagnosis screening — detecting hypertension before it’s diagnosed, identifying cardiovascular risk before an event, screening for sleep apnea before a sleep study. Employers and insurers who fund wearable wellness programs are already collecting data that has clinical screening value; the question is whether and how to activate it.

Where this is heading

More FDA clearances on consumer devices. Blood pressure, sleep apnea detection, glucose estimation (non-invasive), respiratory rate monitoring, and stress biomarkers are all active areas of development for major wearable manufacturers. Each new clearance expands the clinical utility of consumer devices.

RPM reimbursement will expand to consumer devices. The current reimbursement framework was designed for dedicated medical devices. As consumer wearables gain clinical clearances, expect CMS and commercial payers to extend RPM reimbursement to data collected from consumer devices — dramatically expanding the addressable market.

The health data platform becomes the integration layer. As clinical and consumer health data converge, the platform that normalizes, processes, and delivers health data across both contexts becomes critical infrastructure. Product teams building on health data APIs that handle multi-device normalization, clinical-grade processing, and flexible data delivery are positioned for both the wellness and clinical markets.

Preventive monitoring at population scale. The endgame: every consumer wearable serves as a continuous health screening device. Not replacing clinical care, but extending the reach of clinical intelligence to the hundreds of millions of people who wear these devices daily. The data infrastructure to support this — processing billions of data points, computing health scores, detecting anomalies, and routing alerts — is what makes population-scale preventive monitoring feasible.

The boundary between consumer wellness device and clinical monitoring tool is disappearing. The health data infrastructure that spans both worlds will define the next era of connected health.